The BCL-2 family member BOK promotes KRAS-driven lung cancer progression in a p53-dependent manner

A variety of cancer entities are driven by KRAS mutations, which remain difficult to target clinically. Survival pathways, such as resistance to cell death, may represent a promising treatment approach in KRAS mutated cancers. Based on the frequently observed genomic deletions of BCL-2-related ovari...

Descripción completa

Detalles Bibliográficos
Autores principales: Meinhardt, Anna-Lena, Munkhbaatar, Enkhtsetseg, Höckendorf, Ulrike, Dietzen, Michelle, Dechant, Marta, Anton, Martina, Jacob, Anne, Steiger, Katja, Weichert, Wilko, Brcic, Luka, McGranahan, Nicholas, Branca, Caterina, Kaufmann, Thomas, Dengler, Michael A., Jost, Philipp J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8881215/
https://www.ncbi.nlm.nih.gov/pubmed/35091677
http://dx.doi.org/10.1038/s41388-021-02161-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8881215/
https://www.ncbi.nlm.nih.gov/pubmed/35091677
http://dx.doi.org/10.1038/s41388-021-02161-1

Ejemplares similares